Why Pluri Inc.’s (PLUR) Stock Is Down 9.70%
As of Thursday, April 24, Pluri Inc.’s PLUR share price has dipped by 9.70%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Commentary & Analysis
Is Pluri Inc (PLUR) Stock a Good Investment?
Learn more about Pluri Inc's (PLUR) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | PLUR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $14.7 | $282.4 | 8% |
|
| Shares Out (Mil) | 10.1 | 54.0 | 20% |
|
| Institutional Ownership | 24.0% | 93.1% | 11% |
|
| Float (Mil) | 4.4 | 42.2 | 11% |
|
| Beta | 0.75 | 0.94 | 44% |
|
| Avg Daily Volume (000s) | 40 | 482 | 27% |
|
| Price Change (52-week) |
(72.5%) | 59.9% | 8% |
|
| Growth | PLUR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 5.0% | (10.1%) | 47% |
|
| EPS (5yr) | 22.6% | 15.9% | 72 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.3%) | (15.6%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PLUR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($26) | ($43) | 22% |
|
| EPS (TTM) | ($2.832) | ($1.500) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($20) | ($31) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $6 | $4 | 25% |
|
| Enterprise Value (Q1) (Mil) | $55 | $190 | 17% |
|
| Valuation | PLUR | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PLUR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 43.0% | 66.9% | 53% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (80.5%) | (47.7%) | 7% |
|
| ROE | 221.3% | (55.0%) | 98% |
|
| Liabilities to Assets | 149.9% | 29.8% | 98% |
|
| F-Score | 3 | 3 | 18% |
|
Pluri Inc. did not pass any screens on 9/4/2026.
